相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer
Helton Estrela Ramos et al.
ENDOCRINE (2021)
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response
Laura Valerio et al.
ENDOCRINE-RELATED CANCER (2020)
Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)
M. Hu et al.
ANNALS OF ONCOLOGY (2020)
Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer
Lars Bastholt et al.
EUROPEAN THYROID JOURNAL (2016)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
Samuel A. Wells et al.
THYROID (2015)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer
M. Schlumberger et al.
EUROPEAN THYROID JOURNAL (2012)
Biomarker-Based Risk Stratification for Previously Untreated Medullary Thyroid Cancer
Andreas Machens et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
New therapeutic approaches to treat medullary thyroid carcinoma
Martin Schlumberger et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2008)
RET proto-oncogene:: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors
MA Kouvaraki et al.
THYROID (2005)
Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level
A Machens et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
分享论文
